Parallel Bio

Parallel Bio is a biotechnology company pursuing what it calls human-first drug discovery, building a platform that models the human immune system outside the body instead of relying on animal studies. Its core technology is a scalable human immune organoid — 3D, self-assembling lymph-node models derived from donor samples — combined with AI, robotics and end-to-end laboratory automation. The company markets the approach as a "Clinical Trial in a Dish": partner compounds are tested across organoids derived from many different donors to estimate safety and efficacy signals across a diverse population before human trials begin.

The platform is applied to three areas: preclinical drug discovery and target identification through IND, precision medicine and patient stratification, and the training of foundation models on the biological data the automated system generates continuously. Parallel Bio maintains a biobank of donor samples spanning ages, sexes, ethnicities, disease states and genetic backgrounds, which it positions as the substrate for a "map of human biology." Alongside partner-funded work, the company is building internal pipelines of novel disease targets and drug candidates in oncology and autoimmune disease.

The company frames its market rationale around drug-development economics: roughly $2.6 billion and 12.5 years per new drug, with the large majority of candidates failing in human trials despite successful animal studies. Management states a goal of removing about $2 billion and nine years from each candidate's development path, and describes ambitions to reach medicines 10x faster at a fraction of current cost.

Founding story

Robert DiFazio and Juliana Hilliard founded Parallel Bio in San Francisco in 2021 and went through Y Combinator's Summer 2021 batch. At the time DiFazio was at Stanford University, directing an interdisciplinary institute of more than 150 faculty studying human immunology and overseeing a $100M scientific portfolio, after earlier vaccine work with GSK, the NIH and the Danish government; he holds a PhD from the University of Pittsburgh and completed postdoctoral training at Stanford. Hilliard was at Herophilus (formerly System1 Biosciences), adapting brain organoid technology for high-throughput drug discovery. The founders state they started the company to address the reason drugs fail — reliance on animal models — and their first achievement was developing a scalable human immune organoid.

Business model

Parallel Bio operates a platform business, running organoid-based studies for pharmaceutical and biotech partners that test drug and immunotherapy candidates — largely preclinical safety and efficacy work — in human immune models. It simultaneously develops its own drug discovery pipeline in cancer and autoimmune disease, and treats the data generated by its automated platform as a compounding proprietary asset for computational and foundation-model work.

Revenue is derived from collaborations with pharmaceutical and biotech partners who use the organoid platform to evaluate their compounds; the company reported eight pharmaceutical partners, including three Fortune 500 companies, testing more than 50 drugs and immunotherapies.

Traction

Company-reported figures include 50+ compounds tested, 170+ unique patient backgrounds modeled, 87% concordance with human outcomes, and one Phase 1 trial informed by its data. Eight pharmaceutical partners, three of them Fortune 500 companies, have used the platform. In the Centivax collaboration, immune organoids vaccinated with the Centi-Flu universal influenza candidate produced B cells reactive to multiple flu strains, including strains not in the formulation, plus CD4+ and CD8+ T cell activation; Centivax's candidate moved into manufacturing for human trials. Management said it expects a partner to take the first drug co-developed on the platform to the FDA within 12-18 months of the Series A.

Latest developments

In June 2026 Parallel Bio established its U.S. headquarters in Brisbane, California, uniting computational and biological operations, and appointed five advisors: Shane Crotty, Ron Philip, Andre Esteva, Rick Bright and Jason Kichen. It reported working with numerous pharmaceutical partners, including three Fortune 500 companies, testing more than 50 drugs and immunotherapies, and is recruiting scientific and engineering staff in the Bay Area. Company positioning also references growing regulatory openness to non-animal methods and plans for internal pipelines in cancer and autoimmune disease.